Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.
Paaladinesh ThavendiranathanChristian HouboisThomas H MarwickTiffanie KeiSudipta SahaKyle RunecklesFlora HuangTamar ShalmonKevin E ThorpeRossanna C PezoAnca PricaDawn MazeHusam Abdel-QadirKim ConnellyJoyce ChanFilio BilliaColeen PowerKate HannemanBernd J WinterspergerChristine Brezden-MasleyEitan AmirPublished in: European heart journal. Cardiovascular pharmacotherapy (2023)
In patients at increased risk of CTRCD, primary prevention with atorvastatin during anthracycline therapy did not ameliorate LVEF decline, LV remodeling, CTRCD, change in serum cardiac biomarkers, or CMR myocardial tissue changes.Trial registration: NCT03186404.